What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “HRS-4357 injection are administered each time, with dosing for 4 to 6 cycles”In the company’s words, NCT07311694 on ClinicalTrials.gov
- Tested for
- PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
- Main trialPhase 3
- “This study is a randomized, open-label, controlled, multicenter phase III clinical trial, which plans to randomly enroll 370 subjects with advanced metastatic castration-resistant prostate cancer (mCRPC). The efficacy of HRS-4357 versus novel androgen receptor pathway inhibitors (ARPI) in the treatment of PSMA-positive advanced metastatic castration-resistant prostate cancer (mCRPC) will be evaluated based on radiographic progression-free survival (rPFS) assessed by the BIRC.”In the company’s words, NCT07311694 on ClinicalTrials.gov
Coming up1
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Dec 2027 | A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer | |
| Phase 1/2Unknown | 30 Sep 2024 | Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026